These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 15711268

  • 1. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S, Lepor H, Yaffee R, Taneja SS.
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
    Patel R, Lepor H, Thiel RP, Taneja SS.
    Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
    Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J.
    J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
    [Abstract] [Full Text] [Related]

  • 8. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 9. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC.
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
    Hong SK, Park HZ, Lee WK, Kim DS, Lee JS, Doo SH, Jeong SJ, Yoon CY, Byun SS, Lee SE.
    Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
    [Abstract] [Full Text] [Related]

  • 11. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I, Harada K, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Inoue TA, Miyake H.
    Urol Int; 2006 Sep; 76(3):227-31. PubMed ID: 16601384
    [Abstract] [Full Text] [Related]

  • 12. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.
    BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
    [Abstract] [Full Text] [Related]

  • 13. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME, Makarov DV, Humphreys E, Mangold L, Partin AW, Walsh PC.
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR, Lapeyrolerie T.
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [Abstract] [Full Text] [Related]

  • 16. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
    Kinoshita H, Kamoto T, Nishiyama H, Nakamura E, Matsuda T, Ogawa O.
    Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
    [Abstract] [Full Text] [Related]

  • 17. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [Abstract] [Full Text] [Related]

  • 18. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
    Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D.
    J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
    [Abstract] [Full Text] [Related]

  • 19. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
    Shimizu F, Matsuyama Y, Tominaga T, Ohashi Y, Fujime M.
    Urol Int; 2007 Mar; 79(4):356-60. PubMed ID: 18025856
    [Abstract] [Full Text] [Related]

  • 20. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P.
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.